Jeff Yass’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$558K Sell
19,300
-11,900
-38% -$292K ﹤0.01% 9461
2026
Q2
$669K Buy
31,200
+19,700
+171% +$302K ﹤0.01% 9218
2026
Q1
$160K Sell
11,500
-9,500
-45% -$151K ﹤0.01% 11936
2025
Q4
$341K Sell
21,000
-12,300
-37% -$201K ﹤0.01% 9644
2025
Q3
$498K Buy
33,300
+8,100
+32% +$98.7K ﹤0.01% 8958
2025
Q2
$294K Sell
25,200
-4,000
-14% -$36.3K ﹤0.01% 10383
2025
Q1
$217K Buy
29,200
+10,500
+56% +$80.7K ﹤0.01% 10778
2024
Q4
$112K Buy
+18,700
New +$103K ﹤0.01% 11245
2024
Q2
– Sell
-20,700
Closed -$66.4K – 11931
2024
Q1
$66.4K Buy
20,700
+3,800
+22% +$14.7K ﹤0.01% 11437
2023
Q4
$82.8K Sell
16,900
-5,700
-25% -$26K ﹤0.01% 11455
2023
Q3
$123K Sell
22,600
-37,500
-62% -$248K ﹤0.01% 10747
2023
Q2
$403K Buy
60,100
+48,800
+432% +$363K ﹤0.01% 8813
2023
Q1
$100K Sell
11,300
-8,200
-42% -$72.3K ﹤0.01% 11303
2022
Q4
$149K Sell
19,500
-16,200
-45% -$126K ﹤0.01% 10498
2022
Q3
$254K Buy
+35,700
New +$336K ﹤0.01% 10231
2022
Q2
– Sell
-25,300
Closed -$351K – 12777
2022
Q1
$351K Buy
25,300
+10,900
+76% +$171K ﹤0.01% 9879
2021
Q4
$404K Sell
14,400
-16,100
-53% -$493K ﹤0.01% 9740
2021
Q3
$1.04M Sell
30,500
-12,000
-28% -$434K ﹤0.01% 7463
2021
Q2
$1.74M Sell
42,500
-23,300
-35% -$906K ﹤0.01% 6254
2021
Q1
$2.65M Buy
65,800
+43,100
+190% +$2.33M ﹤0.01% 5243
2020
Q4
$1.34M Sell
22,700
-32,400
-59% -$1.67M ﹤0.01% 5999
2020
Q3
$2.68M Sell
55,100
-24,200
-31% -$1.02M ﹤0.01% 4070
2020
Q2
$3.84M Sell
79,300
-45,800
-37% -$1.67M ﹤0.01% 3392
2020
Q1
$3.48M Sell
125,100
-27,600
-18% -$770K ﹤0.01% 3067
2019
Q4
$4.57M Buy
152,700
+67,700
+80% +$1.94M ﹤0.01% 3091
2019
Q3
$2.63M Buy
+85,000
New +$3.47M ﹤0.01% 3717

Other funds holding ADPT

Jeff Yass's ADPT Position: Q3 2026 in Review

Jeff Yass reduced its Adaptive Biotechnologies (ADPT) stake by 2.1% in Q3 2026, selling an estimated $86K and leaving 162,580 shares worth $4.7M. The position accounts for ﹤0.01% of the portfolio, ranked #4549.

Jeff Yass first reported a position in ADPT in Q3 2019 and has held it in 28 quarters since. 334 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • Jeff Yass held 162,580 shares of Adaptive Biotechnologies worth $4.7M as of Q3 2026.
  • Jeff Yass sold 3,501 Adaptive Biotechnologies shares in Q3 2026, an estimated $86K.
  • Adaptive Biotechnologies made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #4549 holding.
  • Jeff Yass first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 28 quarters since.
  • 334 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.